Alan Sawyer

Alan Sawyer

Auto-generated profile, based on publicly available information

Alan Sawyer

EMBL Monoclonal Antibodies Core Facility, Monterotondo-Scalo (RM), Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in Immunity
Verified
Journal Article
Closed access
JKJohn Kim
John Kim
SSSaïd Sif
Saïd Sif
BJBeverly Jones
Beverly Jones
AJAudrey Jackson
Audrey Jackson
JKJoseph Koipally
Joseph Koipally
KGKatia Georgopoulos
Katia Georgopoulos

1 January 2007 in Nature Methods
Verified
Journal Article
Closed access
MTMichael J Taussig
Michael J Taussig
OSOda Stoevesandt
Oda Stoevesandt
CBCarl A K Borrebaeck
Carl A K Borrebaeck
ABAndrew Bradbury
Andrew Bradbury
DCDolores Cahill
Dolores Cahill
MUMathias Uhlen
Mathias Uhlen

1 August 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
XYXiao-Jie Yan
Xiao-Jie Yan
EAEmilia Albesiano
Emilia Albesiano
NZNicola Zanesi
Nicola Zanesi
SYSophia Yancopoulos
Sophia Yancopoulos
ASAlan Sawyer
Alan Sawyer
NCNicholas Chiorazzi
Nicholas Chiorazzi
B cell chronic lymphocytic leukemia (B-CLL) is a clonal overgrowth of CD5+B lymphocytes. In this disease, the B cell antigen receptor (BCR) is intimately linked to disease severity, because patients with BCRs, comprised of unmutated VHgenes, follow a much more aggressive course. This and related observations suggest that B-CLL derives from a B cell subset comprised of restricted BCR structural diversity and that antigen-selection and drive are major factors promoting the disease. Nevertheless, the initiating event(s) that lead to the development of B-CLL are still unclear, in part because of the lack of an animal model that spontaneously evolves the molecular abnormalities that occur in the human disease. Because overexpression of the TCL1 gene in murine B cells leads to a CD5+B cell lymphoproliferative disorder with many of the features of human B-CLL, we studied leukemias emerging in these mice to examine the extent to which their BCRs resemble those in B-CLL. Our data indicate that the immunoglobulin heavy and light chain rearrangements in TCL1 mice display minimal levels of somatic mutations and exhibit several molecular features found in the human disease. Like human B-CLL, TCL1 leukemic rearrangements from different mice can be very similar structurally and closely resemble autoantibodies and antibodies reactive with microbial antigens. Antigen-binding analyses confirm that selected TCL1 clones react with glycerophospholipid, lipoprotein, and polysaccharides that can be autoantigens and be expressed by microbes. This (auto)antigen-driven mouse model reliably captures the BCR characteristics of aggressive, treatment-resistant human B-CLL.

1 December 1995 in Current Biology
Verified
Journal Article
Closed access
SFStephen D. Fuller
Stephen D. Fuller
BGBrent E. Gowen
Brent E. Gowen
SRSigrid Reinsch
Sigrid Reinsch
ASAlan Sawyer
Alan Sawyer
BBBrigitte Buendia
Brigitte Buendia
EKEric Karsenti
Eric Karsenti

1 March 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CCClaudia carissimi
Claudia carissimi
LSLuciano Saieva
Luciano Saieva
JBJennifer Baccon
Jennifer Baccon
PCPieranna Chiarella
Pieranna Chiarella
AMAlessio Maiolica
Alessio Maiolica
LPLivio Pellizzoni
Livio Pellizzoni
The survival motor neuron (SMN) protein is the product of the spinal muscular atrophy disease gene. SMN and Gemin2-7 proteins form a large macromolecular complex that localizes in the cytoplasm as well as in the nucleoplasm and in nuclear Gems. The SMN complex interacts with several additional proteins and likely functions in multiple cellular pathways. In the cytoplasm, a subset of SMN complexes containing unrip and Sm proteins mediates the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs). Here, by mass spectrometry analysis of SMN complexes purified from HeLa cells, we identified a novel protein that is evolutionarily conserved in metazoans, and we named it Gemin8. Co-immunoprecipitation and immunolocalization experiments demonstrated that Gemin8 is associated with the SMN complex and is localized in the cytoplasm and in the nucleus, where it is highly concentrated in Gems. Gemin8 interacts directly with the Gemin6-Gemin7 heterodimer and, together with unrip, these proteins form a heteromeric subunit of the SMN complex. Gemin8 is also associated with Sm proteins, and Gemin8-containing SMN complexes are competent to carry out snRNP assembly. Importantly, RNA interference experiments indicate that Gemin8 knock-down impairs snRNP assembly, and Gemin8 expression is down-regulated in cells with low levels of SMN. These results demonstrate that Gemin8 is a novel integral component of the SMN complex and extend the repertoire of cellular proteins involved in the pathway of snRNP biogenesis.

25 March 2005 in FEBS Letters
Verified
Journal Article
Closed access
CCClaudia carissimi
Claudia carissimi
JBJennifer Baccon
Jennifer Baccon
Marco StracciaMarco Straccia
Marco Straccia
PCPieranna Chiarella
Pieranna Chiarella
AMAlessio Maiolica
Alessio Maiolica
LPLivio Pellizzoni
Livio Pellizzoni